Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow
Use
This test is useful for aiding in the diagnosis of new cases of multiple myeloma or other plasma cell proliferative disorders. It is specifically employed for sorting plasma cells to facilitate fluorescence in situ hybridization analysis. Multiple myeloma is a hematologic neoplasm originating from malignant plasma cells in the bone marrow, characterized by cytogenetic, molecular, and proliferative heterogeneity. Identification and analysis of these cells are crucial in determining disease aggressiveness and selecting appropriate therapeutic approaches.
Special Instructions
Not provided.
Limitations
No significant cautionary statements are indicated for the processing of this test. However, correlation with clinical, histopathologic, and additional laboratory findings is necessary for the final interpretation. Improper specimen collection or handling may affect the test results.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Plasma Cells
Other
Result Turnaround Time
1-7 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
4 mL
Minimum Volume
2 mL
Container
Yellow top (ACD solution A or B); Acceptable: Lavender top (EDTA) or green top (heparin)
Collection Instructions
Invert several times to mix bone marrow. Send bone marrow specimen in original tube. Do not aliquot.
Causes for Rejection
Gross hemolysis, fully clotted specimens will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |
| Refrigerated | 4 days |